Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Chronic Kidney DiseaseKidney Disease
Interventions
DRUG

De Novo Administration of Darbepoetin Alfa

Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY